COMP <GO>
GEHC vs JNJ // FORWARD P/E MULTIPLE
GE HealthCare Technologies Inc. Common Stock (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: GEHC 7
— JNJ 8
▲ FORWARD P/E MULTIPLE LEADER: GEHC
LAST: $76.57 (+0.20%) • MKT CAP: $34.55B
forward-pe
15.4x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GEHC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GEHC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 40.00% | 67.90% | -27.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.20% | 25.50% | -11.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.1x | 18.5x | -7.40 | GEHC | /valuation <GO> |
| Free Cash Flow Yield | 4.19% | 2.97% | +1.22 | GEHC | /fcf-yield <GO> |
| Operating Margin | 13.40% | 34.70% | -21.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 10.10% | 28.50% | -18.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 4.80% | 6.00% | -1.20 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.19% | 0.00% | +0.19 | GEHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.90 | 5.59 | -3.69 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | GEHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.20% | +0.20 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 74.1 | 60.4 | +13.75 | GEHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.08 | +0.07 | GEHC | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 15.4x | 23.0x | -7.60 | GEHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $34.55B | $662.49B | -$627.94B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GEHC REV | JNJ REV | GEHC GROSS % | JNJ GROSS % | GEHC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.63B | $94.19B | 40.0% | 67.9% | $1.41B | $19.70B |
| FY 2024 | $19.67B | $88.82B | 41.7% | 69.1% | $1.35B | $19.84B |
| FY 2023 | $19.55B | $85.16B | 44.0% | 44.0% | $876.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GEHC // BETA 1.15
JNJ // BETA 1.08